SLC2A3 and malignant colon neoplasm: ZBTB7A specifically binds to cis‐acting elements in the promoter region of genes through a DNA‐binding domain and synergistically represses the transcription of target genes through the recruitment of inhibitory complexes (NCoR and HDAC).[40, 41] While Liu et al.[14] reported that reduced ZBTB7A expression in colon cancer patients was positively correlated with the upregulation of the glycolytic genes Glut3, Pfkp, and Pkm and poor patient survival.